RenovoRx (RNXT) News
NASDAQ: RNXTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
1.27-0.06 (-4.51%)
Market open · Delayed 15 min · as of Oct 9, 3:44 PM ET
RNXT news summary
We found 1 recent headline mentioning RenovoRx (RNXT): 1 in the past week and 1 in the past 30 days, most often from Nasdaq. For price context, RNXT is down 4.51% at $1.27. The most recent story, "RenovoRx Enrolls First Patient In UVM-Sponsored Pancreatic Cancer PRISM-TAMP Trial", was published by Nasdaq on Oct 8, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology